The prevalence of colorectal cancer (CRC) is surging across the eight major markets (8MM: the USA, France, Germany, Italy, Spain, UK, Japan and China) due to an aging population and increased mutation testing.
With a projected market expansion from $15.8 billion in 2021 to $21.8 billion in 2031, at a compound annual growth rate (CAGR) of 3.3%, CRC presents a significant growth opportunity.
This uptrend is primarily driven by rising diagnosis rates, notably in key markets like the US and China and approvals of 13 pipeline agents, according to pharma analytics company GlobalData.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze